Sign Up
OverviewAPI
Argenx's subcutaneous autoimmune drug Vyvgart Hytrulo failed to meet primary and secondary endpoints in a Phase III rare bleeding disorder trial, leading to an 8% stock price drop. Acelyrin experienced a significant drop in stock price following an error in the dosing sequence for its clinical development program, causing a review of its lead prospect, izokibep. The biotech is no longer working with the contract research organization responsible for the dosing errors.

Ask a question